Visão geral da empresa
A biomedical technology firm, Biomerica, Inc. engages in the development, patenting, manufacturing, and marketing of diagnostic and therapeutic products designed for the detection and treatment of various medical conditions and diseases on a global scale. The company operates within the Healthcare sector, specifically in the Medical Devices industry, which implies a focus on tangible tools used by medical professionals to assist in patient care and diagnosis. Its operational scale is defined by a market capitalization of $6.64M, annual revenue of $4.46M, and an employee base of 53 individuals. These financial metrics indicate that the entity functions as a small-cap enterprise with limited market presence, where the revenue figure reflects a niche operation rather than broad market penetration, and the low market cap suggests high sensitivity to market sentiment and liquidity constraints typical of smaller public companies.
Saúde financeira
The company reported a revenue of $4.46M over the trailing twelve months, yet it recorded a net income of $-4,025,000 and an EBITDA of $-5,179,000. The substantial gap between the positive revenue of $4.46M and the negative net income reveals a highly fragile cost structure where expenses, including R&D and operational overheads, significantly exceed the gross proceeds from sales. Free cash flow stands at $-1,701,375, indicating that the company is burning cash to fund its operations and growth initiatives, which severely limits its immediate financial flexibility without external capital injections. Three distinct margin metrics highlight the financial pressure: a gross margin of 5.6% suggests a very thin margin on each unit sold, an operating margin of -113.5% indicates that operating expenses are nearly double the revenue generated, and a profit margin of -90.3% confirms that the company loses the vast majority of every dollar it earns. On the balance sheet, the company holds $2.54M in cash against $284,000 in debt, resulting in a debt-to-equity ratio of 6.40, which presents a complex picture of high leverage relative to equity but significant absolute liquidity. The current ratio of 3.25 suggests that the company possesses more than three times the current assets necessary to cover its short-term liabilities, pointing to adequate short-term liquidity despite the negative cash flow. Return on Equity is recorded at -84.3% and Return on Assets at -49.4%, metrics that reveal that management has not yet generated value from its shareholders' capital or asset base, as both ratios are deeply negative due to the net loss position.
Avaliação de valorização
Valuation multiples for Biomerica reflect its unprofitable status, with a trailing P/E ratio listed as N/A due to negative earnings and a forward P/E of 5.64, which implies that the market is pricing in a potential turnaround or future earnings generation to justify current costs. The price-to-book ratio is 1.46, indicating that the stock trades at a premium of roughly 46% above its book value, a situation often seen in small-cap biotech firms where intangible assets like patents are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 1.49 and an EV/EBITDA of -0.85 suggest that investors are willing to pay for the company's revenue potential despite the negative earnings power and negative EBITDA. In terms of trading range, the stock has a 52-week high of $4.88 and a 52-week low of $1.87, meaning the current valuation sits within this band, subject to the immediate volatility of the broader market. The beta value is 0.20, which indicates that the stock price is significantly less volatile than the broader market, moving with much lower intensity to general market swings.
Growth & Income
Growth metrics show a revenue growth year-over-year of -26.0%, while earnings growth is listed as N/A, indicating a contraction in sales that has directly impacted profitability without a stabilizing earnings base. The decline in revenue of 26.0% implies that the company is facing significant headwinds in its sales channels or market demand, and since earnings are N/A, there is no positive earnings growth to offset the revenue decline. As a non-dividend payer, the company distributes no income to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash flow is theoretically retained for operations or used to service debt and cover losses. This growth and income profile characterizes Biomerica, Inc. as a high-risk, high-speculation vehicle that offers no current income yield and is currently contracting in terms of revenue, relying entirely on future product success or strategic pivots to reverse its negative growth trajectory.